(Q35572015)

8 August 2017

1 reference

title

Systemic therapy for colorectal cancer: focus on newer chemotherapy and novel agents (English)

1 reference

8 August 2017

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1016/S1053-4296(03)00047-X

26 March 2024

author name string

Bert H. O'Neil

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14586833

26 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14586833

26 March 2024

publication date

1 October 2003

1 reference

full work available at URL

8 August 2017

https://api.elsevier.com/content/article/PII:S105342960300047X?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S1053-4296(03)00047-X

https://api.elsevier.com/content/article/PII:S105342960300047X?httpAccept=text/plain

26 March 2024

1 reference

https://api.crossref.org/works/10.1016/S1053-4296(03)00047-X

Seminars in Radiation Oncology

26 March 2024

published in

1 reference

8 August 2017

volume

13

1 reference

8 August 2017

issue

4

1 reference

8 August 2017

page(s)

441-453

1 reference

Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma

8 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Prolongation of the disease-free interval in surgically treated rectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Effective surgical adjuvant therapy for high-risk rectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Phase I and pharmacokinetic trial of weekly CPT-11

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Topoisomerase I inhibitors: review and update

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Activity of continuous-infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Protracted continuous infusion of 5-fluorouracil and low-dose leucovorin in patients with metastatic colorectal cancer resistant to 5-fluorouracil bolus-based chemotherapy: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3-T4 unresectable rectal cancer: a phase II IATTGI study

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Ex vivo perfusion of human colon with monoclonal anticolorectal cancer antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Phase I study of recombinant human endostatin in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Epidermal growth factor family receptors and inhibitors: radiation response modulators

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

The role of the ubiquitin-proteasome pathway in apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2803%2900047-X

7 January 2021

Therapy for advanced colorectal cancer

1

1 reference

https://api.crossref.org/works/10.1016/S1053-4296(03)00047-X

X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts

26 March 2024

14

1 reference

https://api.crossref.org/works/10.1016/S1053-4296(03)00047-X

Phase I clinical study of CPT-11. Research group of CPT-11

26 March 2024

17

1 reference

https://api.crossref.org/works/10.1016/S1053-4296(03)00047-X

Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study

26 March 2024

41

1 reference

https://api.crossref.org/works/10.1016/S1053-4296(03)00047-X

Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen

26 March 2024

47

1 reference

https://api.crossref.org/works/10.1016/S1053-4296(03)00047-X

Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothe cin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kappaB activation

26 March 2024

62

1 reference

https://api.crossref.org/works/10.1016/S1053-4296(03)00047-X

26 March 2024

Identifiers

1 reference

8 August 2017

1 reference